Principal Financial Group Inc. Sells 5,320 Shares of Axsome Therapeutics, Inc. $AXSM

Principal Financial Group Inc. cut its position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 1.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 363,114 shares of the company’s stock after selling 5,320 shares during the period. Principal Financial Group Inc.’s holdings in Axsome Therapeutics were worth $66,319,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Vanguard Group Inc. raised its holdings in shares of Axsome Therapeutics by 6.0% in the third quarter. Vanguard Group Inc. now owns 4,180,646 shares of the company’s stock worth $507,739,000 after buying an additional 235,626 shares during the period. Franklin Street Advisors Inc. NC purchased a new position in Axsome Therapeutics during the 4th quarter worth $1,826,000. Aberdeen Group plc increased its holdings in Axsome Therapeutics by 15.5% during the 3rd quarter. Aberdeen Group plc now owns 94,648 shares of the company’s stock worth $11,495,000 after purchasing an additional 12,732 shares during the period. TD Asset Management Inc increased its holdings in Axsome Therapeutics by 107.7% during the 3rd quarter. TD Asset Management Inc now owns 44,192 shares of the company’s stock worth $5,367,000 after purchasing an additional 22,914 shares during the period. Finally, Pictet Asset Management Holding SA increased its holdings in Axsome Therapeutics by 20.4% during the 4th quarter. Pictet Asset Management Holding SA now owns 436,063 shares of the company’s stock worth $79,643,000 after purchasing an additional 73,925 shares during the period. 81.49% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have commented on AXSM shares. Deutsche Bank Aktiengesellschaft set a $280.00 price objective on Axsome Therapeutics in a report on Tuesday. Morgan Stanley lifted their price target on Axsome Therapeutics from $217.00 to $242.00 and gave the company an “equal weight” rating in a report on Tuesday. Piper Sandler restated an “overweight” rating and set a $258.00 target price on shares of Axsome Therapeutics in a research note on Monday. Wolfe Research started coverage on Axsome Therapeutics in a research note on Monday, February 23rd. They set an “outperform” rating and a $230.00 target price on the stock. Finally, Oppenheimer set a $280.00 target price on Axsome Therapeutics in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Axsome Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $251.26.

Insiders Place Their Bets

In other Axsome Therapeutics news, Director Mark Coleman sold 25,000 shares of Axsome Therapeutics stock in a transaction dated Thursday, February 26th. The stock was sold at an average price of $161.11, for a total transaction of $4,027,750.00. Following the completion of the sale, the director owned 47,140 shares of the company’s stock, valued at approximately $7,594,725.40. The trade was a 34.65% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Mark L. Jacobson sold 233 shares of the business’s stock in a transaction dated Tuesday, May 5th. The shares were sold at an average price of $228.18, for a total value of $53,165.94. Following the completion of the transaction, the chief operating officer directly owned 4,517 shares of the company’s stock, valued at approximately $1,030,689.06. This trade represents a 4.91% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 72,628 shares of company stock valued at $12,205,662. 20.60% of the stock is owned by company insiders.

Axsome Therapeutics Stock Down 1.3%

Shares of AXSM stock opened at $219.82 on Friday. Axsome Therapeutics, Inc. has a 1-year low of $96.09 and a 1-year high of $234.29. The stock’s fifty day moving average price is $173.69 and its 200 day moving average price is $164.68. The company has a debt-to-equity ratio of 2.27, a current ratio of 1.39 and a quick ratio of 1.48. The company has a market cap of $11.31 billion, a price-to-earnings ratio of -58.93 and a beta of 0.59.

Axsome Therapeutics (NASDAQ:AXSM) last issued its quarterly earnings results on Monday, May 4th. The company reported ($1.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.41). Axsome Therapeutics had a negative return on equity of 267.16% and a negative net margin of 26.59%.The firm had revenue of $191.20 million for the quarter, compared to analyst estimates of $191.10 million. The firm’s quarterly revenue was up 57.4% on a year-over-year basis. On average, research analysts expect that Axsome Therapeutics, Inc. will post -2.09 earnings per share for the current fiscal year.

Axsome Therapeutics News Summary

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: Strong commercial revenue: Q1 product revenue showed ~57% YoY growth (AUVELITY and SUNOSI drove results), which supports the company’s commercial traction and medium‑term revenue outlook. Axsome 1Q 2026 Financial Results
• Positive Sentiment: Analyst support and price‑target increases: several firms raised targets or reiterated buy/outperform views (supporting upside conviction and liquidity for the stock). AXSM MarketBeat Coverage
• Positive Sentiment: Pipeline catalysts remain: regulatory and clinical moves (AUVELITY label expansion, NDA activity for other programs) could produce medium/long‑term upside if approvals and launches proceed. Business Update & Pipeline Highlights
• Neutral Sentiment: Valuation debate: multiple recent articles discuss whether AXSM’s one‑year share surge leaves it fully priced — this creates two‑sided investor debate between growth expectations and stretched multiples. Assessing Axsome Valuation (Yahoo) Is Axsome Fully Priced? (Yahoo) How AXSM Story Is Shifting (Yahoo UK)
• Neutral Sentiment: Non‑financial PR: the company’s Mental Health Month outreach is reputationally positive but unlikely to move short‑term fundamentals. Axsome Recognizes Mental Health Month
• Negative Sentiment: EPS miss and profitability concerns: GAAP EPS for Q1 came in worse than consensus (wider loss than expected), which highlights near‑term margin and earnings recovery risk despite healthy revenue growth. Q1 Loss Widens; Revenues Jump (Zacks)
• Negative Sentiment: HC Wainwright sharply cut near‑term and FY2026/FY2027 EPS estimates in a May 5 note (though it retained a Buy rating and $290 target) — downward revision of expected earnings can depress short‑term sentiment and raise questions about timing to profitability.
• Negative Sentiment: Insider selling: COO Mark Jacobson sold shares in early May (disclosed SEC filing), which some investors interpret as a modest negative signal even if routine. SEC Filing: Insider Sale

Axsome Therapeutics Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.